Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The need to improve the characterization of CHIP in AL amyloidosis

Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA, discusses the need to better characterize the clinical and molecular features associated with clonal hematopoiesis of indeterminate potential (CHIP) in patients with light chain (AL) amyloidosis. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.